摘要：

An early phase II study of a new analog and an inhibitor of I, -11, was conducted in 62 patients with refractory and by four different treatment schedules in a multiinstitutional cooperative study. -11 therapy resulted in four complete remissions (CRs) and three partial remissions (PRs) in 29 assessable () patients, one PR in three (), one CR and one PR in 11 acute (ALL), and one PR in 15 acute () patients. Single infusion of 200 mg/m2 every 3 to 4 weeks produced no response in both and patients. Sixty-minute infusions of 40 mg/m2/d for 5 days every 3 to 4 weeks or for 3 days weekly produced four CRs (17%) and four PRs (17%) in 24 patients with . Sixty-minute infusions of 20 mg/m2 twice a day for 7 days every 3 to 4 weeks resulted in one CR and two PRs in 12 patients with . No response was seen in an patient by another treatment schedule. -11 was effective in two (15%) of 13 primarily refractory and cases, in two of four relapsed cases, and in seven (17%) of 41 relapsed and refractory cases. Major side effects were (91%) and gastrointestinal (GI) (76%). -11 was shown to be effective against refractory and , and thus deserves further clinical study; the novel antitumor activity mode of this drug predicts no cross-resistance to presently available antitumor drugs.

展开